TY - JOUR
T1 - Five-Year Outcomes with PCI Guided by Fractional Flow Reserve
AU - Xaplanteris, Panagiotis
AU - Fournier, Stephane
AU - Pijls, Nico H J
AU - Fearon, William F
AU - Barbato, Emanuele
AU - Tonino, Pim A L
AU - Engstrøm, Thomas
AU - Kääb, Stefan
AU - Dambrink, Jan-Henk
AU - Rioufol, Gilles
AU - Toth, Gabor G
AU - Piroth, Zsolt
AU - Witt, Nils
AU - Fröbert, Ole
AU - Kala, Petr
AU - Linke, Axel
AU - Jagic, Nicola
AU - Mates, Martin
AU - Mavromatis, Kreton
AU - Samady, Habib
AU - Irimpen, Anand
AU - Oldroyd, Keith
AU - Campo, Gianluca
AU - Rothenbühler, Martina
AU - Jüni, Peter
AU - De Bruyne, Bernard
AU - FAME 2 Investigators
PY - 2018/7/19
Y1 - 2018/7/19
N2 - BACKGROUND We hypothesized that fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) would be superior to medical therapy as initial treatment in patients with stable coronary artery disease. METHODS Among 1220 patients with angiographically significant stenoses, those in whom at least one stenosis was hemodynamically significant (FFR, ≤0.80) were randomly assigned to FFR-guided PCI plus medical therapy or to medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy and were entered into a registry. The primary end point was a composite of death, myocardial infarction, or urgent revascularization. RESULTS A total of 888 patients underwent randomization (447 patients in the PCI group and 441 in the medical-therapy group). At 5 years, the rate of the primary end point was lower in the PCI group than in the medical-therapy group (13.9% vs. 27.0%; hazard ratio, 0.46; 95% confidence interval [CI], 0.34 to 0.63; P<0.001). The difference was driven by urgent revascularizations, which occurred in 6.3% of the patients in the PCI group as compared with 21.1% of those in the medical-therapy group (hazard ratio, 0.27; 95% CI, 0.18 to 0.41). There were no significant differences between the PCI group and the medical-therapy group in the rates of death (5.1% and 5.2%, respectively; hazard ratio, 0.98; 95% CI, 0.55 to 1.75) or myocardial infarction (8.1% and 12.0%; hazard ratio, 0.66; 95% CI, 0.43 to 1.00). There was no significant difference in the rate of the primary end point between the PCI group and the registry cohort (13.9% and 15.7%, respectively; hazard ratio, 0.88; 95% CI, 0.55 to 1.39). Relief from angina was more pronounced after PCI than after medical therapy. CONCLUSIONS In patients with stable coronary artery disease, an initial FFR-guided PCI strategy was associated with a significantly lower rate of the primary composite end point of death, myocardial infarction, or urgent revascularization at 5 years than medical therapy alone. Patients without hemodynamically significant stenoses had a favorable long-term outcome with medical therapy alone. (Funded by St. Jude Medical and others; FAME 2 ClinicalTrials.gov number, NCT01132495.)
AB - BACKGROUND We hypothesized that fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) would be superior to medical therapy as initial treatment in patients with stable coronary artery disease. METHODS Among 1220 patients with angiographically significant stenoses, those in whom at least one stenosis was hemodynamically significant (FFR, ≤0.80) were randomly assigned to FFR-guided PCI plus medical therapy or to medical therapy alone. Patients in whom all stenoses had an FFR of more than 0.80 received medical therapy and were entered into a registry. The primary end point was a composite of death, myocardial infarction, or urgent revascularization. RESULTS A total of 888 patients underwent randomization (447 patients in the PCI group and 441 in the medical-therapy group). At 5 years, the rate of the primary end point was lower in the PCI group than in the medical-therapy group (13.9% vs. 27.0%; hazard ratio, 0.46; 95% confidence interval [CI], 0.34 to 0.63; P<0.001). The difference was driven by urgent revascularizations, which occurred in 6.3% of the patients in the PCI group as compared with 21.1% of those in the medical-therapy group (hazard ratio, 0.27; 95% CI, 0.18 to 0.41). There were no significant differences between the PCI group and the medical-therapy group in the rates of death (5.1% and 5.2%, respectively; hazard ratio, 0.98; 95% CI, 0.55 to 1.75) or myocardial infarction (8.1% and 12.0%; hazard ratio, 0.66; 95% CI, 0.43 to 1.00). There was no significant difference in the rate of the primary end point between the PCI group and the registry cohort (13.9% and 15.7%, respectively; hazard ratio, 0.88; 95% CI, 0.55 to 1.39). Relief from angina was more pronounced after PCI than after medical therapy. CONCLUSIONS In patients with stable coronary artery disease, an initial FFR-guided PCI strategy was associated with a significantly lower rate of the primary composite end point of death, myocardial infarction, or urgent revascularization at 5 years than medical therapy alone. Patients without hemodynamically significant stenoses had a favorable long-term outcome with medical therapy alone. (Funded by St. Jude Medical and others; FAME 2 ClinicalTrials.gov number, NCT01132495.)
KW - Aged
KW - Angina Pectoris/therapy
KW - Antihypertensive Agents/therapeutic use
KW - Coronary Disease/drug therapy
KW - Coronary Stenosis/drug therapy
KW - Drug-Eluting Stents
KW - Female
KW - Follow-Up Studies
KW - Fractional Flow Reserve, Myocardial
KW - Humans
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Myocardial Infarction/epidemiology
KW - Percutaneous Coronary Intervention
KW - Platelet Aggregation Inhibitors/therapeutic use
KW - Retreatment/statistics & numerical data
U2 - 10.1056/nejmoa1803538
DO - 10.1056/nejmoa1803538
M3 - Journal article
C2 - 29785878
SN - 0028-4793
VL - 379
SP - 250
EP - 259
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 3
ER -